ロード中...
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors targeting BRCA1/2 mutations are available for treating patients with high-grade serous ovarian cancer. These treatments may be more appropriately directed to patients who might respond if the tumor tissue is additionally tested by next-generation s...
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7069205/ https://ncbi.nlm.nih.gov/pubmed/32164585 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6693-y |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|